Mile­stone Phar­ma preps a leap in­to PhI­II car­dio study with $55M round backed by No­vo

A lit­tle more than two months af­ter scor­ing the proof-of-con­cept da­ta that he was look­ing for, Joe Olive­to is steer­ing Mile­stone Phar­ma­ceu­ti­cals in­to a Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER